Gregory Covino - Biogen Insider

BIIB -- USA Stock  

USD 297.73  5.69  1.95%

Chief Accounting Officer, VP of Fin. and Controller

Mr. Gregory F. Covino is Chief Accounting Officer, Vice President Finance of Biogen Inc. From June 2017 to December 2017, Mr. Covino also served as our interim Principal Financial Officer. From March 2010 to April 2012, Mr. Covino served at Boston Scientific Corporationrationration, a medical device company, as Vice President, Corporationrationrate Analysis and Control, having responsibility for the company internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrate Accounting from 1999 to 2002.
Age: 51  VP Since 2017      
617-679-2000  http://www.biogen.com
Covino has served as our Vice President, Finance and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporationrationrationration, a medical device company, as Vice President, Corporationrationrationrate Analysis and Control since March 2010, having responsibility for the company internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrationrate Accounting from 1999 to 2002. He received his B.S. in Business Administration from Bryant University.

Gregory Covino Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 16.44 % which means that it generated profit of $16.44 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.26 % meaning that it created $24.26 on every $100 dollars invested by stockholders.
The company currently holds 5.93 B in liabilities with Debt to Equity (D/E) ratio of 42.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biogen has Current Ratio of 3.17 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 7300 people.Biogen (BIIB) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 7,300 people. Biogen is listed under Pharmaceutical Products category by Fama And French industry classification.

Biogen Leadership Team

Richard Mulligan, Director, Ph.D
Paul McKenzie, President, Ph.D
Michel Vounatsos, President
Sanjay Jariwala, President
George Scangos, CEO, Ph.D
Alfred Sandrock, President, Ph.D
Spyros ArtavanisTsakonas, President, Ph.D
Alexander Denner, Director, Ph.D
Douglas Williams, EVP
JeanPaul Kress, President
Eric Rowinsky, Director
Adriana Karaboutis, EVP
Mark Hernon, President, MBA
Kenneth Pietro, President
Adam Koppel, President, MBA
Stephen Sherwin, Director, Ph.D
Caroline Dorsa, Director
Michael Ehlers, President, Ph.D
Ginger Gregory, President
Chirfi Guindo, President
Susan Alexander, President
Catherine Steele, President
Daniel Karp, President
Paul Clancy, CFO, MBA
Steven Holtzman, President
Anirvan Ghosh, President, Ph.D
Nancy Leaming, Director
Lynn Schenk, Director
Camille Lee, President
Brian Posner, Director
Gregory Covino, VP
Anabella Villalobos, President, Ph.D
Stelios Papadopoulos, Chairman, Ph.D
John Cox, EVP, MBA
Robert Pangia, Director
Matt Griffiths, President
Jeffrey Capello, President

Stock Performance Indicators

Did you try this?

Run Idea Analyzer Now
   

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
All  Next Launch Idea Analyzer

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Biogen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.